<DOC>
	<DOCNO>NCT01387204</DOCNO>
	<brief_summary>GSK1120212 reversible highly selective allosteric inhibitor MEK1 MEK2 activation kinase activity currently develop treatment malignant melanoma . This Phase I , open-label , non-randomized , single-dose study design characterize absorption , distribution , metabolism , elimination ( ADME ) single oral dose MEK inhibitor [ 14C ] GSK1120212 solution male subject solid tumor malignancy . A sufficient number subject enrol complete approximately four evaluable subject . Following completion study , subject may elect continue dose GSK1120212 rollover study , MEK114375 .</brief_summary>
	<brief_title>Study Investigate Absorption , Distribution , Metabolism Elimination 14CGSK1120212</brief_title>
	<detailed_description />
	<mesh_term>Trametinib</mesh_term>
	<criteria>1 . Male 18 year old old . 2 . Written inform consent provide 3 . Body weight great equal 45 kg BMI great equal 19 kg/m2 less equal 35 kg/m2 ( inclusive ) . 4 . Able swallow retain oral medication . 5 . Histologically cytologically confirm diagnosis solid tumor . 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . 7 . Agree use one contraception method list protocol time first dose study medication sixteen week last dose study medication . 8 . A history regular bowel movement ( approximately per day ) . 9 . Adequate baseline organ function list protocol . 1 . Currently receive cancer therapy specify protocol . 2 . Serious and/or unstable preexist medical psychiatric disorder , condition . 3 . Any major surgery within last four week . 4 . Unresolved toxicity equal great Grade 2 previous anticancer therapy except alopecia . 5 . An occupation within past 12 month require monitor radiation exposure , nuclear medicine procedure excessive xrays . 6 . Radiation exposure previous three year period 10 mSv expose ionize radiation background result work radiation category A ( classify ) worker result research study . 7 . History interstitial lung disease pneumonitis . 8 . Known immediate delay hypersensitivity reaction idiosyncrasy dimethyl sulfoxide ( DMSO ) . 9 . Current use prohibit medication describe protocol . â€¢ Use anticoagulants warfarin permit . 10 . History RVO CSR . Predisposing factor RVO CSR . Visible retinal pathology consider risk factor RVO CSR : Evidence new optic disc cup Intraocular pressure great 21 mm Hg measure tonography . 11.1 . Symptomatic untreated leptomeningeal brain metastasis spinal cord compression . ( Previously treat stable CNS disease great 3 month , asymptomatic corticosteroid , stable dose corticosteroid least 1 month prior study Day 1 permit ) . 11.2 . Receiving enzyme induce antiepileptic drug ( EIAEDs ) . 12 . History acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within past 6 month . 13 . QTcB great equal 480 msec . 14 . History evidence current clinically significant uncontrolled arrhythmia . 15 . History evidence current great equal Class II congestive heart failure . 16 . Active gastrointestinal disease condition ( e.g. , gastrectomy , bariatric surgery , small bowel large bowel resection , cholecystectomy ) . 17 . A history know Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus , Hepatitis C Virus . 18 . Alcohol drug abuse within six month prior screen . 19 . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug excipients . 20 . Participated clinical trial receive investigational product within 30 day five halflives twice duration biological effect investigational product ( whichever longer ) 1st dose . 21 . Where participation study would result donation blood blood product excess 500 mL within 56 day period . 22 . Mentally legally incapacitate .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>MEK inhibitor</keyword>
	<keyword>elimination</keyword>
	<keyword>Phase 1</keyword>
	<keyword>GSK1120212</keyword>
	<keyword>cancer</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>oncology</keyword>
	<keyword>radiolabeled ADME</keyword>
</DOC>